AI Article Synopsis
- The study aimed to assess the real-world effectiveness of brolucizumab injections for patients with neovascular age-related macular degeneration (nAMD) who did not respond to previous treatments.
- Results showed that while visual acuity (BCVA) remained stable, anatomical improvements were noted, such as decreased central foveal thickness (CFT) and reduced presence of subretinal fluid (SRF) and pigment epithelial detachment (PED) after switching to brolucizumab.
- The safety profile was acceptable, with a low incidence of intraocular inflammation-related adverse events reported among the patients.
Article Abstract
Purpose: To investigate the first-year real-world anatomical and functional outcomes of intravitreal brolucizumab injection in eyes with refractory neovascular age-related macular degeneration (nAMD).
Study Design: Retrospective observational study.
Methods: nAMD patients who showed poor response to previous anti-vascular endothelial growth factor (VEGF) agents were switched to brolucizumab. Functional and anatomical outcomes were evaluated at initial treatment of nAMD, after treatment with other anti-VEGF agents and after switching and treating with brolucizumab for 1 year. Safety profile was also evaluated after brolucizumab injection. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), and the presence of fluid in different compartments (intraretinal fluid [IRF], subretinal fluid [SRF], pigment epithelial detachment [PED]) were assessed at each time point.
Results: A total of 40 eyes of 40 patients were included in the study. BCVA remained unchanged throughout treatment (p > 0.05). CFT did not change after treatment with other anti-VEGF agents (p = 0.588) but decreased after switching to brolucizumab (p < 0.001). SFCT decreased after treatment with other anti-VEGF agents (p = 0.025) but not after switching to brolucizumab (p = 0.236). Presence of SRF (p = 0.001) and PED (p = 0.001) decreased significantly after switching to brolucizumab, despite their persistence with prior treatments using other anti-VEGF agents. However, IRF persisted even after switching to brolucizumab (p = 0.745). Intraocular inflammation (IOI)-related adverse events were reported in 3 eyes (7.14%).
Conclusion: Analysis of first-year real-world outcomes after switching to brolucizumab in nAMD patients refractory to other anti-VEGF agents showed improved anatomic outcomes, limited functional improvement and low incidence of IOI-related adverse events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10384-024-01134-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: This study evaluates the efficacy of intravitreal injections (IVI) of faricimab in patients with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelium detachment (RPED) resistant to other anti-VEGF agents.
Material And Methods: The study included 61 patients (61 eyes) with nAMD previously treated with aflibercept and/or brolucizumab IVIs. Three groups were formed: group 1 received aflibercept IVI (32 eyes), group 2 received brolucizumab IVI (14 eyes), and group 3 received aflibercept followed by brolucizumab IVI (15 eyes).
The Safety of Recently Approved Therapeutics in Age-Related Macular Degeneration.
Int Ophthalmol Clin
January 2025
University of Nevada, Reno School of Medicine, Reno, NV.
Recent developments in treatments for both forms of advanced age-related macular degeneration (AMD) have led to the approval of multiple agents and modalities within the last few years. Five new medications for both neovascular AMD (nAMD) and geographic atrophy (GA) secondary to nonexudative AMD (neAMD) have been FDA-approved within the last 5 years, along with a new device designed for sustained drug delivery for nAMD. In nAMD, the newest agents approved by the FDA are brolucizumab (Novartis Pharmaceuticals, Basel, Switzerland), faricimab (F.
View Article and Find Full Text PDFInitial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India - Multicentric, real-world study.
Indian J Ophthalmol
December 2024
Retina Department, Complete Eye Care Centre Manish Chamber, Mayur Vihar Phase-2, Delhi, India.
Purpose: To evaluate the anatomic and visual outcomes and safety profile of initial Indian eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab.
Methods: This retrospective multicentric, real-world study enrolled consecutive eyes with nAMD that were treated with IVI brolucizumab after it was launched in India in October 2020. Data collected for each eye included best-corrected visual acuity (BCVA), central subfield thickness (CSFT), subretinal fluid (SRF), and intraretinal fluid (IRF) status at 6, 12, and 24 months follow-up.
[Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies].
Vestn Oftalmol
November 2024
S.M. Kirov Military Medical Academy, Saint Petersburg, Russia.
Brolucizumab, an angiogenesis inhibitor, is a single-chain fragment of a humanized antibody used to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Although registration studies are the primary source of information on the new drug, post-marketing studies allow for further exploration and expansion of previous knowledge about its effectiveness, safety, and dosing regimens. This study summarizes the experience with brolucizumab from real-world clinical practice studies.
View Article and Find Full Text PDFEffects on corneal endothelium of intravitreal injection of anti-VEGF drugs.
Cutan Ocul Toxicol
December 2024
Department of Sense Organs, Sapienza University of Rome, Rome, Italy.
Article Synopsis
- * Researchers analyzed a group of 133 patients with retinal diseases like age-related macular degeneration (AMD), collecting data on corneal endothelial cell counts before and after multiple injections of different anti-VEGF medications.
- * The primary goal was to establish a link between these injections and any significant decrease in endothelial cell counts in the treated eyes compared to untreated ones, while also comparing the toxicity levels between various anti-VEGF drugs used in the treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!